Nephros Inc (NEPH)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $33.15M
Last updated: Nov 17, 2026 at 11:00 AM ET
Nephros Inc (NEPH) Financials: Revenue, Profit and Cash Flow
Nephros reported revenue of $18.79M for the fiscal year ended Dec 31, 2025, up 32.7% from the year before. That year, net income was $1.19M with a net margin of 6.4%, operating cash flow was $1.65M and free cash flow was $1.65M. The quarter ended Sep 30, 2026 had revenue of $5.62M and net income of $512.00K.
Revenue and Margins
The operating margin was 6.1% in the fiscal year ended Dec 2025, the highest of the 8 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $2.32M, a compound annual rate of 26.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $18.79M | +32.7% | 61.9% | 6.1% | 6.4% |
| Dec 2024 | $14.16M | -0.5% | 61.6% | 0.0% | 0.5% |
| Dec 2023 | $14.24M | +42.7% | 59.0% | -11.2% | -11.1% |
| Dec 2022 | $9.97M | -2.4% | 47.4% | -43.5% | -71.2% |
| Dec 2021 | $10.22M | +19.3% | 55.1% | -31.8% | -37.8% |
| Dec 2020 | $8.56M | N/A | 57.4% | -49.9% | -52.9% |
| Dec 2019 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2018 | $5.69M | +49.3% | 56.3% | -53.0% | -58.5% |
| Dec 2017 | $3.81M | +64.2% | 60.2% | -58.4% | -21.2% |
| Dec 2016 | $2.32M | N/A | 55.8% | -123.7% | -130.7% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 1508.1% from the year before. In the quarter ended Sep 2026, net income rose 51.9% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $18.79M | $14.16M | $14.24M | $9.97M | $10.22M | $8.56M | $0 | $5.69M | $3.81M | $2.32M |
| Cost of revenue | $7.16M | $5.44M | $5.83M | $5.24M | $4.58M | $3.65M | -$6.08M | $2.48M | $1.52M | $1.03M |
| Gross profit | $11.63M | $8.72M | $8.40M | $4.73M | $5.63M | $4.91M | $6.08M | $3.20M | $2.29M | $1.29M |
| Research and development | $1.34M | $906.00K | $873.00K | $1.25M | $1.50M | $2.76M | $3.09M | $1.54M | $1.00M | $1.08M |
| Operating income | $1.15M | $6.00K | -$1.59M | -$4.33M | -$3.25M | -$4.28M | -$3.15M | -$3.02M | -$2.23M | -$2.87M |
| Net income | $1.19M | $74.00K | -$1.57M | -$7.11M | -$3.87M | -$4.53M | -$3.18M | -$3.33M | -$809.00K | -$3.03M |
| EBITDA | $1.21M | $133.00K | -$1.42M | -$3.92M | -$2.98M | -$4.22M | -$3.01M | -$2.85M | -$1.97M | -$2.58M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.62M | $6.02M | $5.21M | $4.73M | $4.76M | $4.42M | $4.88M | $3.87M | $3.52M | $3.25M | $3.52M | $3.25M |
| Gross profit | $3.29M | $4.03M | $2.99M | $2.76M | $2.92M | $2.79M | $3.15M | $2.48M | $2.15M | $1.91M | $2.19M | $2.02M |
| Operating income | $501.00K | $1.21M | $97.00K | $18.00K | $314.00K | $248.00K | $566.00K | $317.00K | $206.00K | -$317.00K | -$200.00K | -$649.00K |
| Net income | $512.00K | $1.20M | $140.00K | $70.00K | $337.00K | $237.00K | $558.00K | $318.00K | $183.00K | -$289.00K | -$138.00K | -$654.00K |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $391.00K by $5.01M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $13.64M | $11.21M | $11.86M | $11.00M | $17.65M | $18.51M | $11.63M | $10.56M | $4.98M | $2.68M |
| Current assets | $11.22M | $8.30M | $8.40M | $8.26M | $13.63M | $15.15M | $8.30M | $8.17M | $3.81M | $1.26M |
| Cash and equivalents | $5.40M | $3.76M | $4.31M | $3.63M | $6.97M | $8.25M | $4.17M | $4.58M | $2.19M | $275.00K |
| Total liabilities | $3.44M | $2.63M | $3.50M | $2.12M | $2.90M | $2.94M | $3.94M | $3.76M | $3.03M | $2.01M |
| Short-term debt | $391.00K | $348.00K | $446.00K | $71.00K | $248.00K | $229.00K | $1.07M | $1.42M | $711.00K | $0 |
| Long-term debt | N/A | N/A | N/A | $1.00K | $95.00K | $846.00K | $613.00K | $843.00K | $954.00K | $838.00K |
| Shareholder equity | $10.20M | $8.59M | $8.36M | $5.59M | $11.70M | $12.52M | $4.67M | $3.80M | $1.95M | $667.00K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $15.30M | $15.77M | $13.79M | $13.64M | $13.25M | $12.24M | $11.78M | $11.21M | $10.39M | $11.10M | $11.42M | $11.86M |
| Total liabilities | $2.76M | $3.80M | $3.09M | $3.44M | $3.24M | $2.64M | $2.49M | $2.63M | $2.21M | $3.17M | $3.24M | $3.50M |
| Cash and equivalents | $4.55M | $4.70M | $4.02M | $5.40M | $5.17M | $5.07M | $4.08M | $3.76M | $2.46M | $3.08M | $3.63M | $4.31M |
| Shareholder equity | $12.55M | $11.97M | $10.70M | $10.20M | $10.01M | $9.60M | $9.29M | $8.59M | $8.17M | $7.93M | $8.18M | $8.36M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 100.0% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.65M | -$492.00K | $827.00K | -$3.23M | -$1.42M | -$6.90M | -$2.28M | -$3.66M | -$77.00K | -$2.32M |
| Capital expenditures | $0 | $55.00K | $75.00K | $137.00K | $36.00K | $239.00K | $14.00K | $0 | $14.00K | $45.00K |
| Free cash flow | $1.65M | -$547.00K | $752.00K | -$3.37M | -$1.45M | -$7.14M | -$2.29M | -$3.66M | -$91.00K | -$2.36M |
| Dividends paid | N/A | N/A | N/A | $276.00K | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | $0 | -$50.00K | -$75.00K | -$137.00K | -$85.00K | -$239.00K | -$151.00K | -$991.00K | $0 | -$45.00K |
| Financing cash flow | -$5.00K | -$5.00K | -$79.00K | $34.00K | $237.00K | $11.22M | $2.02M | $7.05M | $1.99M | $1.19M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$150.00K | $681.00K | -$1.67M | $230.00K | $99.00K | $994.00K | $322.00K | $1.30M | -$623.00K | -$501.00K | -$672.00K | -$237.00K |
| Capital expenditures | N/A | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $55.00K | $0 | $75.00K |
| Free cash flow | N/A | N/A | -$1.67M | $230.00K | $99.00K | $994.00K | $322.00K | $1.30M | -$623.00K | -$556.00K | -$672.00K | -$312.00K |
Frequently Asked Questions About NEPH
What is Nephros' annual revenue?
Nephros reported revenue of $18.79M for the fiscal year ended Dec 31, 2025.
How fast is Nephros' revenue growing?
Revenue was up 32.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 23.5%.
Is Nephros profitable?
Yes. Nephros reported net income of $1.19M for the fiscal year ended Dec 31, 2025, with a net margin of 6.4%.
How much free cash flow does NEPH generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $1.65M minus capital expenditures of $0 produced free cash flow of $1.65M.
How much debt does Nephros have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $391.00K and cash and equivalents of $5.40M.
NEPH pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors